Skip to main content

CHLORZOXAZONE

Generic: CHLORZOXAZONE

Verified·Apr 23, 2026
Manufacturer
McNeil
NDC
24470-923
RxCUI
197502
Route
ORAL
ICD-10 indication
M79.10

Affordability Check

How much will you actually pay for CHLORZOXAZONE?

In 30 seconds, see every legitimate way to afford CHLORZOXAZONE — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About CHLORZOXAZONE

What is this medication?

Chlorzoxazone is a prescription medication categorized as a muscle relaxant. It is primarily used to relieve pain and discomfort caused by muscle strains, sprains, and other musculoskeletal injuries. The medication works by acting on the spinal cord and subcortical areas of the brain to inhibit the transmission of nerve impulses that cause muscles to spasm, thereby helping to relax the affected area and improve mobility.

This drug is typically prescribed as one part of a comprehensive treatment program that includes rest and physical therapy. It is generally intended for short-term use during the recovery phase of an acute injury rather than for the management of chronic conditions. Because chlorzoxazone can cause side effects such as drowsiness or dizziness, patients are usually advised to avoid driving or operating heavy machinery until they understand how the medication affects them.

Copay & patient assistance

Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program for more details.

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Prescribing information

From the FDA-approved label for CHLORZOXAZONE. Official source: DailyMed (NLM) · Label effective May 23, 2023

Indications and usage
INDICATIONS AND USAGE Chlorzoxazone is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Chlorzoxazone does not directly relax tense skeletal muscles in man.
Dosage and administration
DOSAGE AND ADMINISTRATION Usual Adult Dosage: One tablet (250 mg) three or four times daily. Initial dosage for painful musculoskeletal conditions should be two tablets (500 mg) three or four times daily. If adequate response is not obtained with this dose, it may be increased to three tablets (750 mg) three or four times daily. As improvement occurs dosage can usually be reduced.
Contraindications
CONTRAINDICATIONS Chlorzoxazone is contraindicated in patients with known intolerance to the drug.
Warnings
WARNINGS Serious (including fatal) hepatocellular toxicity has been reported rarely in patients receiving chlorzoxazone. The mechanism is unknown but appears to be idiosyncratic and unpredictable. Factors predisposing patients to this rare event are not known. Patients should be instructed to report early signs and/or symptoms of hepatotoxicity such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, or jaundice. Chlorzoxazone should be discontinued immediately and a physician consulted if any of these signs or symptoms develop. Chlorzoxazone use should also be discontinued if a patient develops abnormal liver enzymes (e.g., AST, ALT, alkaline phosphatase and bilirubin). The concomitant use of alcohol or other central nervous system depressants may have an additive effect. Usage in Pregnancy: The safe use of chlorzoxazone has not been established with respect to the possible adverse effects upon fetal development. Therefore, it should be used in women of childbearing potential only when, in the judgment of the physician, the potential benefits outweigh the possible risks.
Adverse reactions
ADVERSE REACTIONS After extensive clinical use of chlorzoxazone-containing products, it is apparent that the product is well tolerated and seldom produces undesirable side effects. Occasional patients may develop gastrointestinal disturbances. It is possible in rare instances that chlorzoxazone may have been associated with gastrointestinal bleeding. Drowsiness, dizziness, lightheadedness, malaise, or overstimulation may be noted by an occasional patient. Rarely, allergic-type skin rashes, petechiae, or ecchymoses may develop during treatment. Angioneurotic edema or anaphylactic reactions are extremely rare. There is no evidence that the drug will cause renal damage. Rarely, a patient may note discoloration of the urine resulting from a phenolic metabolite of chlorzoxazone. This finding is of no known clinical significance.

Label text is reproduced as-is from the FDA-approved label. We do not paraphrase, summarize, or omit. Content above is for informational purposes only and is not medical advice. Always consult your prescribing clinician or pharmacist before making decisions about your medication.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Medicare Part D coverage

How CHLORZOXAZONE appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-04-30).

Covered by plans

34%

1,891 of 5,509 plans

Most common tier

Tier 2

On 55% of covering formularies

Prior authorization required

54%

of covering formularies

TierFormularies on this tierShare
Tier 1 (preferred generic)22
31%
Tier 2 (generic)39
55%
Tier 3 (preferred brand)8
11%
Tier 4 (non-preferred brand)2
3%

Step therapy: 0% of formularies

Quantity limits: 63% of formularies

Coverage breadth: 71 of 65 formularies

How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).

Prior authorization & coverage

PayerPAStep therapyCopay tier

Medicare Part D

Medicare Part D

Medicare Part D

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.